Media Room | Latest Updates in Psychedelic Medicine

May 10, 2022

WESANA HEALTH OUTLINES ACCELERATED DRUG DEVELOPMENT PATHWAY

CHICAGO and TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven…

https://wesanahealth.com/wp-content/themes/impeka/impeka/images/empty/thumbnail.jpg 150 150 Wesana Health Wesana Health https://wesanahealth.com/wp-content/themes/impeka/impeka/images/empty/thumbnail.jpg May 10, 2022 May 10, 2022

Press Releases

March 29, 2022

Wesana Health CEO Daniel Carcillo to Speak at Several Leading Investor and Industry Events

CHICAGO and TORONTO, March 29, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF),…

Press Releases

March 22, 2022

Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant

CHICAGO and TORONTO, March 22, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF),…

Brain Injury Awareness Month: New Hope With Psychedelic Medicine

Psychedelic Stock Watch

https://psychedelicstockwatch.com/psychedelic-stock-news/brain-injury-awareness-month-new-hope-with-psychedelic-medicine

https://wesanahealth.com/wp-content/uploads/2022/03/article_Brain_Injury_Awareness_cover.png 800 450 Wesana Health Wesana Health https://wesanahealth.com/wp-content/uploads/2022/03/article_Brain_Injury_Awareness_cover.png March 15, 2022 March 31, 2022

Press Releases Research and Development

March 14, 2022

Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013

Pre-IND Meeting is a Significant Milestone in the Clinical Development of SANA-013, Defining the Pathway to Initiate in-Human Clinical Trials…

Press Releases

March 11, 2022

Wesana Provides Updates on Build-out of Third Clinic

Naperville clinic to open Spring 2022 CHICAGO and TORONTO, March 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana”…

From NHL Enforcer To CEO: Daniel Carcillo’s New Company Wants To Treat Traumatic Brain Injury With Psilocybin

Forbes

https://www.forbes.com/sites/amandasiebert/2021/01/22/from-nhl-enforcer-to-ceo-daniel-carcillos-new-company-wants-to-treat-traumatic-brain-injury-with-psilocybin/?sh=6217757b1af6

Press Releases Research and Development

January 18, 2022

Wesana Health Announces Positive Findings From Animal Study on Novel Depression Treatment Protocol Combining Psilocybin and Cannabidiol

Wesana’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen…

Press Releases Research and Development

January 11, 2022

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

The meeting is scheduled for March 11, 2022 CHICAGO and TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana”…

Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments

Yahoo Finance

https://finance-yahoo-com.cdn.ampproject.org/c/s/finance.yahoo.com/amphtml/news/wesana-health-clinics-surpass-4-123200172.html

November 19, 2021

CEO Daniel Carcillo: Bad Trips Are “The Secret Sauce” To Healing

Ex-NHLer’s Wesana Health is Bringing Much-Needed Big Data to Psychedelic Medicine

The Cannabis Investor

https://www.thecannabisinvestor.ca/ex-nhlers-wesana-health-is-bringing-much-needed-big-data-to-psychedelic-medicine/